In this CCO Nephrology podcast episode, hear from nephrologists Pietro Canetta, MD, MS, and Andy Bomback, MD, PhD, experts in clinical management and research on glomerular diseases as they discuss key updates in managing IgAN. Faculty highlight the importance of a comprehensive supportive care regimen to protect patients’ kidneys and prevent progression of disease. In addition, they review the merits and place in therapy of novel and emerging therapies.

Topics include:

• Supportive care as the foundation of IgAN management
• Place in therapy for new and emerging agents
  • Targeted-release formulation of budesonide
  • Endothelin receptor antagonists (eg, sparsentan)
  • Factor B inhibitors (eg, iptacopan)
• The role of clinical trial involvement

Learn more about IgA nephropathy with educational activities and resources here:

• CME-certified text module with animated pathophysiology video and patient voice audio clip
• ClinicalThought commentaries
• Resources on IgAN from the American Kidney Fund

In this CCO Nephrology podcast episode, hear from cardiologist Erin D. Michos, MD, MHS, FACC, FAHA, FASE, FASPC, and nephrologist Mark J. Sarnak, MD, MS, as they discuss new and emerging therapies designed to target residual inflammatory risk associated with ASCVD and CKD.  

 Episode outline:  

• Colchicine: inhibition of NLRP3 inflammasome assembly/activation
• Canakinumab (anti–IL-1β monoclonal antibody)
• Ziltivekimab (anti–IL-6 monoclonal antibody)
• Other emerging targets/therapies

To learn more about targeting residual risk associated with systemic inflammation, find more educational activities and resources with the links below:  

• CME-certified text module with animated pathophysiology video and faculty voice audio clips
• ClinicalThought commentaries
• Podcast episode 1, discussing residual risk associated with systemic inflammation and the role of cardiologists and nephrologists in mitigating risk in ASCVD and CKD
• Podcast episode 2, discussing novel therapeutic approaches to address residual inflammatory risks in patients with ASCVD and CKD

In this CCO Nephrology podcast episode, hear from cardiologist Erin D. Michos, MD, MHS, FACC, FAHA, FASE, FASPC, and nephrologist Mark J. Sarnak, MD, MS, as they explore new and emerging strategies to target residual risk associated with systemic inflammation in patients with ASCVD and CKD.  

 Episode outline:  

• The relationship among systemic inflammation, ASCVD, and CKD
• The role of cardiologists and nephrologists in screening and mitigating systemic inflammation

To learn more about targeting residual risk associated with systemic inflammation, find more educational activities and resources with the links below:  

• CME-certified text module with animated pathophysiology video and faculty voice audio clips
• ClinicalThought commentaries
• Podcast episode 2, discussing novel therapeutic approaches to address residual inflammatory risks in patients with ASCVD and CKD
• Podcast episode 3, featuring faculty discussion of new and emerging therapies to target inflammatory risk in patients with ASCVD and CKD